Evaluation of antifungal spectrum of Cupferron against Candida albicans

Francesca Palma1, Marina Acunzo1, Roberta Della Marca1

  • 1Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138, Naples, Italy.

Microbial Pathogenesis
|August 8, 2024
PubMed

Insights

Cupferron demonstrates significant antifungal activity against Candida albicans, inhibiting growth and virulence factors at non-toxic concentrations. This compound shows promise as a novel therapeutic option for candidiasis infections.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Candida albicans causes numerous human infections, from superficial to life-threatening systemic diseases.
  • Virulence factors like biofilm and hyphal transition exacerbate C. albicans infections, increasing healthcare burdens.
  • There is an urgent need for new antifungal agents to combat resistant or severe fungal infections.

Purpose of the Study:

  • To evaluate the anti-Candida potential of N-Nitroso-N-phenylhydroxylamine ammonium salt (cupferron).
  • To assess cupferron's efficacy against standard and clinical strains of Candida albicans.
  • To investigate cupferron's impact on C. albicans virulence factors.

Main Methods:

  • In vitro cytotoxicity testing of cupferron on human microglial cells (HMC-3).
  • Antifungal activity assessment using disk diffusion, broth microdilution, and time-killing curve analyses.
  • Scanning electron microscopy (SEM) for visualizing antifungal effects and evaluation of virulence factor inhibition.

Main Results:

  • Cupferron exhibited non-toxic effects on HMC-3 cells at concentrations up to 100 μg/mL.
  • Minimum inhibitory concentrations (MICs) ranged from 50 to 100 μg/mL against tested C. albicans strains.
  • Cupferron demonstrated fungistatic activity up to 100 μg/mL and effectively counteracted fungal virulence at MIC and sub-MIC levels.

Conclusions:

  • Cupferron possesses significant in vitro antifungal activity against Candida albicans.
  • The compound effectively inhibits key virulence determinants of C. albicans.
  • Cupferron represents a potential new therapeutic candidate for treating Candida albicans infections.